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Background: The goal of the research project Greifswald
Approach to Individualized Medicine (GANI_MED) is to
implement individualized diagnostic and treatment strate-
gies using clinical routine data from our university hospital.
To identify new risk factors and biomarkers of diseases, we
are in the process of establishing large patient cohorts for
several highly prevalent disease conditions including heart
failure, stroke, renal insufficiency, and metabolic syndrome.
These patient cohorts will be compared to well character-
ized samples from a population-based cohort study (the
Study of Health in Pomerania; SHIP) in a case-control
setting. One important aspect of the GANI_MED project is
to use clinically obtained data for research purposes and to
ensure adequate standardization and quality of these data.
Aim: The aim is to standardize the routine data acquisition
in the clinical context and to achieve strict quality control
and standardization of these data.
Methods: The clinical characterization of the patient
cohorts includes standardized questionnaires, basic medical
and anthropometric examinations (e.g. blood pressure and
somatometric measurements) as well as more complex
procedures such as ultrasonographic imaging techniques.
We developed several methods to ensure adequate stan-
dardization of the data. For the medical history, a
standardized interview syntax was programmed and imple-
mented in a mobile data capture software with data
validation function using a tablet PC for medical needs.
Data is stored in a data warehouse, and a medical history
report is created for clinical use.
For all relevant clinical examinations, standard operating
procedures (SOPs) were developed which are in line with the
standards used within SHIP to ensure best possible compa-
rability between the patient cohorts and the control sample.
All physicians and technicians involved in the data acquisi-
tion process are trained, certified and supervised regularly.
The obtained data are monitored closely, and in certification
procedures, inter- and intra-examiner differences—as
assessed by Bland-Altman-Plots—must not exceed 5%.
For basic medical examinations including e.g. measurement
of weight, height and blood pressure, identical devices
across all cohorts are used. Regular device certifications,
calibrations and comparative studies are performed. Indi-
vidual feedback to each examiner is provided, and regular
meetings with all examiners are organized on a weekly
basis to ensure optimal exchange and discussions between
examiners and the data quality management.
Conclusion: GANI_MED extends current research concepts
of individualized medicine by in-depth standardization of
clinical routine data. This will be the basis for establishing
and validating individualized prevention, diagnostics and
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Array-based assay systems allow the determination of
hundreds of molecular parameters in a single experiment.
Within the last decade protein microarray technologies
achieved robust analytical performance and allowed to
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screen for a multitude of parameters requiring only minimal
amounts of sample material [1–4].
In this presentation the current state of protein microarrays
for biomarker discovery, validation and diagnosis will be
reviewed together with future demands for their application
within the field of personalized medicine.
In addition, biomarker discovery activities will be discussed
within the context of the FDA’s critical path initiative
and the European public–private “Innovative Medicines
Initiative” (IMI) [5,6].
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THE ROLE OF LABORATORY MEDICINE IN
HEALTHCARE: QUALITY REQUIREMENTS OF
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MANAGEMENT IN PROSPECTIVE MEDICINE
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In the last ten years, the area of ELISA, Luminex and
multiplex protein chip technology has developed and
enthusiastically applied to an enormous variety of biolog-
ical questions. However, the degree of stringency required
in data analysis appears to have been underestimated. As a
result, there are numerous published findings that are of
questionable quality, requiring further confirmation and/or
validation. In the course of feasibility and validation studies
a number of key issues in research, development and
clinical trial studies must be outlined, including those
associated with laboratory design, analytical validation
strategies, analytical completeness and data managements.
The scope of the following präsentation should provide
assistance for defining key parameters in assay evaluation
and validation in research and clinical trial projects in
prospective medicine.
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Objectives: Prostate cancer is the most common cancer in
men and the prevalence is expected to increase within an
ageing society. Screening for elevated serum levels of
prostate-specific antigen (PSA) is frequently used for early
detection of prostate cancer in healthy men in order to
enhance the chance of curative treatment. However, serum
PSA has a low cancer specificity resulting in a false
positive rate of 70% and more. Reducing the number of
unnecessary prostate biopsies triggered by false-elevated
PSA serum values would have a highly beneficial effect on
both patients and healthcare costs in an ageing population.
Methods: Using the proprietary UNIarray® technology
we initiated a study to identify autoantigen markers that
distinguish between prostate cancer and healthy men. This
panel was further verified employing protein microarray
chips.
Results: Stratified patient samples were incubated with the
currently largest collection of recombinant human proteins
available for screening purposes to detect autoantibodies
against specific targets. Using plasma samples from 20
prostate cancer (pre-surgery samples, Gleason score of
resected prostate: 7–9) and 20 age-matched samples of non-
diseased men (PSA: 0.1–0.68 ng/ml) we identified more
than 150 prostate cancer candidate autoantigens. These
autoantigen proteins were subsequently purified and printed
on a protein microarray. For a first verification the protein
biochip was used to test plasma or serum samples of 40
prostate cancer patients (Gleason score>7), 40 age-matched
men with elevated PSA and negative biopsy (mostly
diagnosed as mainly benign hypertrophy & prostatitis)
and 40 age-matched control men with normal PSA over
several years. Bioinformatic analysis using different methods
such as support vector machine (SVM) algorithms, classifi-
cation trees, neuronal nets and a quantitative thresholdmethod
combined with 10-fold cross validation were used to select the
most promising candidates for further technical development.
A subset of the marker candidates on the biochip prototype
already discriminates prostate cancer patients from persons
with elevated PSA and biopsy negative with a diagnostic
specificity of 73% and a sensitivity of 68%. A multicenter
validation study is in progress.
Conclusion: Serum autoantibodies are promising biomarker
candidates for improvement of specificity of prostate cancer
detection.
S174 EPMA Journal (2011) 2 (Suppl 1):S173–S180
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Prostate cancer is the most common cause of lethal cancer in
men and the prevalence is expected to increase within an
ageing society. Screening for elevated serum levels of
prostate-specific antigen (PSA) and/or digital rectal examina-
tion (DRE) is frequently used for early detection of prostate
cancer. Elevated PSA levels and/or positive DRE result trigger
prostate biopsy to confirm cancer in suspect cases. Prostate
biopsy is an inconvenient procedure which is associated with
surgery-related risks and does not confirm prostate cancer in
up to 70 % of cases or more. This leaves patients with an
uncertainty about a possible disease and causes further
examinations including further biopsies. Reducing the
number of unnecessary prostate biopsies would have a
highly beneficial effect on both patients and healthcare
costs in an ageing population. Consequently, for differ-
entiation between benign prostate disease (mainly
benign hypertrophy & prostatitis) and malign prostate
cancer, we are developing a protein biochip for a serum-
based assay with a novel set of diagnostic markers
discovered using the proprietary UNIarray® technology.
Briefly, stratified patient samples were incubated with the
currently largest collection of recombinant human proteins
blotted on PVDF membranes for screening purposes to
detect autoantibodies against specific targets. Using plasma
samples from 20 prostate cancer and 20 age-matched
controls we have identified more than 150 prostate cancer
specific candidate autoantigens. All autoantigen candidates
detected in patient samples were recombinantly expressed,
purified and printed on a protein microarray.
For a first verification of these novel markers the
protein biochip was used to test 40 plasma samples of
prostate cancer patients (Gleason score>7), 40 plasma
samples of age-matched persons with elevated PSA and
biopsy negative (mostly diagnosed as mainly benign
hypertrophy & prostatitis) and 40 plasma samples of
age-matched control persons with normal PSA over
several years as well as normal DRE. Bioinformatical
methods such as support vector machine (SVM) algo-
rithms, classification trees, neuronal nets and a quanti-
tative threshold method combined with 10-fold cross
validation are used to select the most promising candidates
for further technical development. A subset of the marker
candidates on the biochip prototype already discriminates
prostate cancer patients from persons with elevated PSA and
biopsy negative with a diagnostic specificity of 73% and a
sensitivity of 68%.
Conclusion: The UNIarray® technology platform comprises
the systematic identification of autoantibody signatures in the
serum or plasma of patients. These results may be used for e.g.
patient stratification in clinical studies, treatment selection,
therapy monitoring, and disease progression testing or
diagnostic purposes. A verification study of the prostate
cancer marker candidates with>500 samples is ongoing.
MULTIPLEX X MAP ANALYSIS—ANALYTICAL
TOOL FOR PERSONALISED MEDICINE
Vrzalová J, Topolčan O
Immunoanalytic laboratory, Faculty Hospital and Faculty
of Medicine in Pilsen, Charles University in Prague,
Czech Republic
Rapidly developing and expanding multiplex immunoanaly-
sis opens door for precise and more adequate study of
complex processes of physiology and pathophysiology.
Cytokines, chemokines and growth factors are excellent
candidates for multiplexed analysis because of their complex
interrelationships and their complex effect on organism.
We have established the assessment of cytokines, angio-
genic factors, adhesive molecules, hormones, tumour
markers and other biomarkers in various biological
materials of human, mouse and rat origin by multiplex
immunoanalysis in our laboratory. Clinical application of
this method is very wide. xMAP technology is based on
binding of studied proteins to the antibodies linked to
microspheres with internal spectral code referring to
protein identity. The amounts of the bound proteins are
determined by a second antibody connected with fluorescent
molecule. The measurement is performed on special flow
cytometer (luminex instrument), which determines the spec-
tral code of microspheres—the identity of proteins—after an
excitation by first laser and after an excitation by second laser
it detects the amount of second antibodies on microspheres—
the quantity of protein in sample. The concentrations of
proteins are assessed according to standard calibration curves
assayed with unknown samples.
Because of the complex nature of the method, it is important
for an investigator to plan precisely the multiplex study before
the application. There are three main questions:
1. Which blood sample type is adequate?
2. A number of proteins that is possible to analyse in
one well?
3. Is the sensitivity of the method sufficient for all
proteins measured?
Currently multiplex is mainly the task for the research field
but introduction of this method in clinical use can be expected
in the near future, because of its advantages: small sample
volume used, complex information on the markers received
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and potentially low costs at application. However, before the
use of multiplex inflammatory biomarkers analyses in clinical
practice, the essential step is to standardise the pre-analytical
and analytical rules and normal ranges.
Support: This study was supported by the research project
VZ MSM 0021620819.
THE “4S” CONCEPT: HOW TO AUGMENT
THE PREDICTIVE VALUE OF PRECLINICAL
RESEARCH
Moiseeva EV, Semushina SG, Bojenko VK
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The evident achievements of modern experimental
medicine conceal the recognizable signs of a coming
collapse: many preclinically efficient drugs demonstrated
no efficacy in clinical trials. Thus, abundant resources
(funds, animals, scientific potential) are spent to produce
findings with no clinical value. This compels us to
replace the current paradigm of preclinical research
(based on randomization and averaging, and unilateral
rodent models) with a new concept (multilevel set of
complementary models, personalized animal data based
on predictive markers, stratified sampling and subgroup-
ing within control and experimental groups to reveal
both positive and negative effect of a drug in each
experiment). This personalized approach originated from
our anti-breast cancer drug testing practice [1] and is
currently described by the “4S”concept:
Personalized concept Standard paradigm
S Set of complementary models (including
spontaneous and non-SPF ones)→
Multilevel models
Unilateral models
S Stratification (representatives from sensitive,
resistant, and intermediate clusters are
used to generate stratified sampling)
Randomization
S Subgrouping approach to analyze data Averaging
S Stages of testing → both direct and




We created three original inbred mouse strains (RB-strains,
carriers of Rb(8.17)1Iem Robertsonian translocation) with
various but high incidences of spontaneous (naturally
arisen) mammary cancer (MC) rarely associated with
ovary/uterus cancer and/or leukemia/lymphoma. Set of
inbred strains with high (RB-strains), low (BALB/
cJCitMoise), and intermediate (A/WySnJCitMoise) inciden-
ces of spontaneous MC and collection of transplantable
tumour cell lines, including various types of MC, T- and B-
cell lymphoma/leukemia are maintained. Special documen-
tation system permits to follow each laboratory mouse
during the whole it’s lifespan individually (as a patient).
Newly developed classification of murine MC allows to
disclose the similarities with human breast cancer pathology.
Our anticancer drug testing procedure commonly follows
consecutive steps from in vitro (stage 0: sensitivity of cancer
and immune cells are tested separately) to in vivo: trans-
planted (stage 1: preliminary tests to discover proper dosage,
application time, et cetera using aged mice from non-SPF
colony as recipients of tumor cells from spontaneous MC),
spontaneous (stage 2: therapeutic application in females with/
without MC extirpation), and precancerous (stage 3: preven-
tive regimen in females before spontaneous MC occurrence).
Several experimental data may illustrate the advantages of
our concept to be in line with personalized/predictive/
preventive holistic medicine. We collected intravital blood
samples from intact mice and showed that some laboratory
clinical parameters predicted (1) duration of subclinical
period of MC and correlated with a stage of tumour growth
in transplanted models; (2) time of spontaneous MC
detection in precancerous females of RB-strains (addition-
ally, trace element markers were used); and (3) both
beneficial or non-beneficial effects of immunotherapy by
local interleukin-2. Importantly, modern statistical
approaches (including artificial neural networks) were used
to construct relevant mathematical models.
In summary, we propose the statements of personalized
concept as a few achievable steps to improve experimental
research quality and predictability.
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KNOWLEDGE TRANSFER AND PATENTING
STRATEGY IN PREDICTIVE MEDICINE
Walkenhorst J
PROvendis GmbH, Mülheim/Ruhr, Germany
Several trends have evolved over the last years which have
facilitated knowledge transfer in predictive medicine from
academia to industry, e.g.:
(i) A strong need to find new sources of innovation in the
pharmaceutical industry in order to avoid “pipelines
drying up”—softening the “not invented here”-argument
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(ii) Personalized medicine will gain more importance
(iii) Pharmaceutical industry becomes more science-
oriented. In fact, it even becomes more “academic”
in structure e.g. establishing “Centers of Excellence”
(iv) Academia becomes more “business-like” with an
increasing need for third party funding and a
redefinition of the “mission of the university”.
Knowledge transfer can occur in many different ways.
However, this paper will focus on the transfer of technologies.
Technology transfer offices (TTOs), which comprehensively
were established in most countries not before the turn of the
millennium, have demonstrably gained (more) maturity. In
particular the life sciences have profited there from.
This contribution investigates current trends in technology
transfer regarding predictive medicine, focusing on
biomarker-licensing. It further outlines different concepts
for improvements along this line.
Licensing as well as patenting activities have taken off in most
industries, including life sciences. Also, biomarkers from all
relevant areas of “-omics” are per se patentable, thus fulfilling
an important prerequisite for commercialization.
Accordingly, the number of respective licensing agreements
is swiftly increasing (as of April 28th MedtrackTM lists 455
agreements relating to biomarkers).
Typical agreements relate to biomarker discovery and co-
development but also to specific biomarkers(−sets). A
recent example is the Takeda-Zinfandel agreement covering
TOMM40.
Most agreements are concluded between biotech and
pharmaceutical companies. However, academic research
institutions are a rich source of biomarkers which is
reflected in the number of invention reports e.g. at
PROvendis. Indeed, several licenses have been signed and
there continues to be multitudinous negotiations between
academia/TTOs and industry. Several biomarkers which
have been identified in academia are now being marketed,
including e.g. the multigene-panel of MammaPrintTM.
Yet, the path of a biomarker from the academia to industry
seems to be particularly winding.
To some degree this is misleading. Biomarkers are relevant
for different steps in drug development and application.
Inter alia, biomarkers are essential for studying mode of
action of drug candidates. In this case, a detailed validation of
a biomarker (by numerous independent scientific studies) will
be more important to the industry than a monopoly position.
Thus, although no license agreements will be signed,
academia contributes enormously to drug development.
To some degree this is due to difficulties of establishing
approved diagnostic biomarkers on the market as (often)
significant efforts will be necessary convincing physicians and
providers of other (allegedly competing) diagnostic tools that
there will be a win-win-situation for all stakeholders.
To a large extend, however, reasons can be found within
academia. These include the difficulty of conducting/
funding large scale studies with sufficient statistical power
according to clinical development standards (however,
initiatives, such as the German National Biomarker data-
base, look promising). They also include more general
issues of the present technology transfer landscape such as
an ongoing need to educate scientists.
Specialised Session: Role of Laboratory Medicine in
PPPM
ROLE OF LABORATORY TESTING OF POLY-
MORPHIC ALLELE VARIANTS OF GENE CYP2C9
OF ISOENZYME 2C9 OF CYTOCHROME P450
IN PREDICTIVE, PREVENTIVE AND PERSONAL-
ISED MEDICINE ON EPILEPTOLOGY
Pilugina M, Dmitrenko D, Shnayder N
Krasnoyarsk State Medical University named after Prof. V.F.
Vojno-Jasenetsky, Krasnoyarsk, Russian Federation
Epilepsy is a widespread socially important chronic disease of
brain which is treated for many years but 30% of the patients
with epilepsy should take antiepileptic drugs for the life term.
Client-centred approach in case of epilepsy drug therapy
include assessment of the factors which influence the inter-
and individual variability, in particular pharmacokinetic
parameters changes which are due to the patient’s physiologic
and pathologic characteristics. In the present contribution an
overview about our present knowledge how polymorphic
genes can influence the VPA drugs efficacy is provided. Some
emphasis will be given to different forms of cytochrome P450
which are of importance for VPA metabolism.
The purpose of the research is the assessment of the role of
CYP2C9 gene polymorphisms of the isoenzyme 2C9 of
cytochrome P450 of the liver as unmodified risk factor of
adverse drug events development in case of intake of an
average therapeutic doses of VPA drugs at patients with
epilepsy and epileptic syndromes.
Materials and methods: Sampling included 41 cases
(patients with epilepsy and epileptic syndromes). Patients
were from 1 up to 60 years of age, the median was
23 years. Methods: analysis of doses of VPA preparations,
TDM of VPA level in serum, study of readings in biochemical
blood analyses (level of aspartate aminotransferase—AsAT,
alanine aminotransferase—AlAT, bilirubin, amylase, complete
albumen), illustrating functional activity of liver; video-EEG-
monitoring; pharmacogenetic testing of polymorphisms of
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gene CYP2C9 (chromosome10q24.1-24.3) of isoenzyme
2C9: wild-type allele variant CYP2C9*1 without mutation,
mutant-type allele variants (CYP2C9*2—single nucleotide
replacement of cytosine by thymine in the position 430;
CYP2C9*3—single nucleotide replacement of adenine by
cytosine in position 1075). Blood sampling, picking out
of DNA and molecular-genetic studies were performed
after a patient had given a documentary confirmation to
be followed up and for filling in a patient’s case record
which is composed in accordance with the aim and tasks
of the research.
Results: All the carriers of mutant polymorphous allelic
variants CYP2C9*2 and CYP2C9*3, both homozygous and
heterozygous carriers and also in case of their combination
(for example, genotype CYP2C9*2/CYP2C9*3) had 100%
occurrence of treatment-emergent adverse events in case of
standard usage of VPA drug dosage in accordance with the
Pharmacopeia (20–30 mg/kg/per day for children, 20 mg/
kg/per day for adults) even during the daily dose titration
(10–15 mg/kg/per day for children, 5–10 mg/kg/per day for
adults). The homozygous carrier of the gene CYP2C9 of
the minor allelic variant of the isoenzyme 2C9 of
cytochrome P450 had the most severe adverse drug
reactions in the form of epileptic seizures aggravation,
cognitive and behavioral disorders in case of standard usage
of VPA drug dosage (kg/ body weight per daily).
Summary: Personal approach to the VPA drug dosage in the
therapy of epilepsy with children and adult patients is
justified clinically. It is of medical, social and economic
effectiveness in epileptology.
ACTIVITY OF ANTISEPTIC SOLUTIONS IN RELA-
TION TO THEIR PHYSICOCHEMICAL PROPERTIES
Gjorgjeska B, Dimova C
Faculty of Medical Sciences, Krste Misirkov bb, POB
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Knowing antiseptic activity of chemical disinfectant sub-
stances has a great practical value in Predictive, Preventive
and Personalised Medicine.
It is evident that there is the need for defining standard
technique for quantitative determination of bactericidal
activity of chemical disinfectant substances, as well as the
need for defining parameter for comparing various chem-
ical disinfectants. Solution of phenol (5%) was considered
as referent standard for evaluation of efficacy of disinfec-
tant aqueous solutions. Suitability of phenol coefficient for
evaluation of nonphenolic disinfectants is still opened
question. On the other side the methods for evaluation of
antiseptic activity of disinfectant aqueous solutions are
microbiological.
The aim of this study is to develop a new empirical
coefficient which is capable to express the various
physicochemical properties of disinfectant solutions on
bactericidal activity. The basic duty of this parameter
(Disinfection Activity Coefficient of Solution—DACS)
is to express capability for comparison and prediction of
disinfectant activity. The DACS index, which is the sum
of four terms (fluidity, surface tension, redox potential
and osmolality), results in good correlation with the
activity at different disinfectant aqueous solutions. The
DACS index can be calculated using additive and
statistical models. Statistical model is adequate for
evaluation of different disinfectant solutions because
of better expressing the bactericidal activity then
additive model. For analyze of various dilutions of
one disinfectant there is no significant difference
between this two models. The usefulness of DACS is
demonstrated for analyze of bactericidal activities on
different disinfectant solutions containing boric acid,
chlorhexidne, chlorhexidine with cetrimide, chloroxyle-
nol, chlorophen, eosin, hydrogen peroxide, phenyl
mercury borate, povidon-iodine, thiomersal, tosilchlor-
amide and phenol. Results of bactericidal activities
obtained from microbiological tests on Staphylococcus
aureus was compared with activities predicted through
DACS. In conclusion, it is considered good correlation
between experimental and calculated values for bacte-
ricidal activity.
REPRODUCIBILITY OF 3-PART DIFFERENTIAL
HEMATOLOGY ANALYZER MEDONIC CA620: 3
YEARS OF EXPERIENCE WITH 90 000 SAMPLES
IN MACEDONIA
Ruskovska T, Kamcev N, Kamceva G, Siljanovski N
Faculty of Medical Sciences, University “Goce Delcev”,
Stip, Macedonia
Background: Three-part differential hematology analyzer,
as a common equipment of hematology departments in
routine clinical laboratories, is indispensable tool for
early diagnostics and monitoring of therapy in different
hematological and infectious diseases. Besides regular
calibration and quality control according to good
laboratory practice, a periodical check of analyzer’s
reproducibility is essential for getting the high quality
results that contribute well to the improvement of the
patients care. According to manufacturer’s data Medonic
CA620 hematology analyzer has the best overall
reproducibility of all 3-part differential hematology
analyzers currently available on Macedonian market.
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Aim of the study: The aim of our study was to determine
the reproducibility of hematology analyzer Medonic CA620
after 3 years of intensive exploitation and 90 000 samples
analyzed. We have also compared the obtained data with
results from similar study conducted after 9 months of
intensive exploitation of the same analyzer and with data
given from manufacturer.
Material and methods: Reproducibility of 3-part differential
hematology analyzer Medonic CA620 was assessed by
measuring four different fresh samples, each counted 12
times. The reproducibility of five parameters: hemoglobin
(HGB), red blood cells (RBC), mean corpuscular volume
(MCV), white blood cells (WBC) and platelets (PLT) was
expressed as coefficient of variation (CV) of twelve
measurements.
Results: For hemoglobin the following results were
obtained: 13.4±0.1 g/dL, CV=0.75%; 12.3±0.1 g/dL,
CV=0.81%; 10.8±0.1 g/dL, CV=0.93%; 10.0±0.1 g/dL,
CV=1.00% (mean CV=0.87%). The results for hemo-
globin reproducibility obtained from previous study
were 12.9±0.1 g/dL, CV=0.78%, and the manufacturer
states for hemoglobin CV=0.60%.
For RBC the following results were obtained: 5.10±0.06×
106/μL, CV=1.18%; 4.86±0.05×106/μL, CV=1.03%; 4.51±
0.05×106/μL, CV=1.11%; 3.41±0.02×106/μL, CV=0.59%
(mean CV=0.98%). The results for RBC reproducibility
obtained from previous study were 4.63±0.03×106/μL,
CV=0.65%, and the manufacturer states for red blood
cells CV=0.85%.
For MCV the following results were obtained: 93.8±0.5 fL,
CV=0.53%; 87.0±0.3 fL, CV=0.34%; 86.0±0.2 fL, CV=
0.23%; 70.1±0.2 fL, CV=0.29% (mean CV=0.35%). The
results for MCV reproducibility obtained from previous
study were 78.0±0.2 fL, CV=0.26%, and the manufacturer
states for mean corpuscular volume CV=0.50%.
For WBC the results were the following: 17.2±0.2×103/μL,
CV=1.2%; 12.3±0.2×103/μL, CV=1.6%; 6.7±0.1×103/μL,
CV=1.5%; 4.6±0.1×103/μL, CV=2.2% (mean CV=1.6%).
The results for WBC reproducibility obtained from previous
study were 4.6±0.1×103/μL, CV=2.2%, and the manufac-
turer states for white blood cells CV=2.0%.
Finally, for PLT the results were the following: 292±12×
103/μL, CV=4.1%; 210±7×103/μL, CV=3.3%; 188±8×
103/μL, CV=4.3%; 94±8×103/μL, CV=8.5% (mean CV=
5.1%). The results for PLT reproducibility obtained from
previous study were 233±8×103/μL, CV=3.4%, and the
manufacturer states for platelets CV=3.3%.
Conclusion: Besides the intensive 3-years exploitation and
90 000 samples analyzed, the 3-part differential hematology
analyzer Medonic CA620 still has an excellent reproduc-
ibility of results both for normal and pathological samples
that is a robust basis for the high quality measurements in
medical care, including corresponding services for preven-
tive medicine.
TECHNOLOGY PLATFORM FOR STABLE ISOTOPE
LABELLING AND NON-INVASIVE ANALYSIS:
METHODOLOGIES AND PROSPECTS FOR PRE-
DICTIVE, PREVENTIVE AND PERSONALISED
MEDICINE
Egorova-Zachernyuk TA
Protein Labelling Innovation (PLI), BioScience Park,
Archimedesweg 27 2333 CM Leiden, The Netherlands
Protein Labelling Innovation (PLI) is an independent
research oriented technology platform company that was
found by Dr. Sc. Tatiana Egorova-Zachernyuk in Leiden in
2000. PLI is based in a part of Europe well-known for its
expertise in these fields. PLI’s major ambitions are to
develop novel technologies for the pharmaceutical and food
& nutrition market. One of the goals is to contribute with
the developed multidisciplinary approaches to the novel
strategy in healthcare: predictive, preventive and personal-
ised medicine (PPPM).
Core business of PLI consists of R&D activities: cost-effective
biosynthetic preparation and characterisation of biologically
active molecules of various complexity, from small com-
pounds up to complex biomolecules such as humanmembrane
proteins, in particular drug targets. This includes labelling with
stable isotopes (13C,15N, 2H). PLI has unique expertise in
biosynthetic preparation of high-valuable molecules from
prokaryotes, archea and eukaryotes (algae, yeast, fungus,
insect and mammalian cell lines).
PLI provides a proprietary technology on “Compositions
and methods for stable isotope labelling of biological
compounds” (PCT/NL03/00514). In November 2010 the
patent is granted in Australia, AU 2004256368, and in
January 2011 in Russian Federation, RU 2409657 C2. The
patent application is pending in Europe, USA, Canada and
Japan. PLI is offering license on the technology platform
related with stable isotope (13C, 15N, 2H) labelling.
As an example, preparation of stable-isotope labelled drug
target – human histamine H1 receptor for ssNMR structural
analysis will be shown. Labelling with stable isotopes in
mammalian and insect cell lines opens prospects for the
preparation of high-valuable biomolecules for various
applications: metabolomics, proteomics, structural biology,
PPPM. Novel approaches on FT-IR rapid assessment to new
sources of specific biomolecules and to the level of stable
isotope enrichment will be demonstrated. In addition, rapid
assessment to the level of unsaturation of fatty acids will be
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demonstrated. The technologies have a potential value to
accelerate drug discovery and drug design and to develop
new products for predictive diagnostics.
The PLI’s technology platform opens new prospects for
both, cost-effective labelling of biologically active mole-
cules and fast non- invasive analysis, which is crucial for
the development of new PPPM strategies.
Implementations and future outlook include:
& Quantification of novel diagnostics biomarkers in
various branches of medicine and disease areas such
as cancer, cardiovascular, diabetes, allergic, neurode-
generative diseases and other;
& Non-invasive fast screening of new sources of
bioingredients and health-promoting biomolecules to
be applied in functional foods and personalized
therapies;
& Structure-functional insights in interactions of health-
promoting biomolecules and/or drugs with the drug
targets with the aim to prevent pathologies and develop
individualised strategies.
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